STVN · Stevanato Group S.p.A.
$20.90
-0.24% last session
End-of-day data · close of 2026-09-11
Market cap
$6B
Enterprise value
$6B
Trailing P/E
35.5
Forward P/E
24.9
Dividend yield
0.0%
Beta
0.75
Avg volume
0M
Employees
6K
Daily Change %
-0.24%
5 Days Change
-1.32%
10 Days Change
-5.55%
30 Days Change
-3.85%
60 Days Change
3.32%
Month to Day Change
-2.27%
Year to Day Change
0.96%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — STVN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
UBS
Neutral$23.00
+9.8% vs priceMorgan Stanley
Equal-Weight$19.00
-9.3% vs priceCitigroup
Buy$26.00
+24.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Maintains | Neutral | $28.00 → $23.00 |
| 2026-06-16 | TD Cowen | Initiates | Buy | $0.00 → $25.00 |
| 2026-03-06 | Morgan Stanley | Maintains | Equal-Weight | $24.00 → $19.00 |
| 2026-03-05 | Citigroup | Maintains | Buy | $32.00 → $26.00 |
| 2026-03-05 | Keybanc | Maintains | Overweight | $37.00 → $32.00 |
| 2025-12-02 | Morgan Stanley | Maintains | Equal-Weight | $26.00 → $24.00 |
| 2025-11-11 | Morgan Stanley | Maintains | Equal-Weight | $24.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.0% above the 50-day MA ($20.48).
- Price vs 200-day MA: Trading 14.5% above the 200-day MA ($18.26).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($13.38) and high ($27.51).
STVN Price Chart
Loading chart for STVN…
Fundamentals
About Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$129B -37.6% YTD
BDX
Becton, Dickinson and Company
$48B 20.1% YTD
MDLN
Medline Inc.
$44B -18.9% YTD
ALC
Alcon Inc.
$32B -12.8% YTD
RMD
ResMed Inc.
$32B -7.9% YTD
WST
West Pharmaceutical Services, I
$24B 22.8% YTD
SOLV
Solventum Corporation
$15B 13.6% YTD
BAX
Baxter International Inc.
$13B 27.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.